Monte Historical Financial Ratios

GLUE Stock

USD 5.26 0.23 4.19%

Monte Rosa is lately reporting on over 95 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 2.42 or Days Sales Outstanding of 0.67 will help investors to properly organize and evaluate Monte Rosa Therapeutics financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

About Monte Financial Ratios Analysis

Monte Rosa TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Monte Rosa investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Monte financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Monte Rosa history.

Monte Rosa Financial Ratios Chart

At present, Monte Rosa's Free Cash Flow Yield is projected to slightly decrease based on the last few years of reporting. The current year's Operating Cash Flow Per Share is expected to grow to 0.60, whereas Capex To Depreciation is forecasted to decline to 0.47.

Price To Sales Ratio Days Sales Outstanding Ev To Sales Inventory Turnover

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Monte Rosa Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Monte Rosa sales, a figure that is much harder to manipulate than other Monte Rosa Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Inventory Turnover

A ratio showing how many times a company's inventory is sold and replaced over a period, indicating the efficiency of inventory management.

Most ratios from Monte Rosa's fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Monte Rosa Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Monte Rosa Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

	2024	2025 (projected)
Interest Debt Per Share	0.58	0.66
Revenue Per Share	0.92	0.82

Interest Debt Per Share Revenue Per Share

Monte Rosa fundamentals Correlations

	Price To Sales Ratio	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe	Ev To Operating Cash Flow	Pe Ratio
Price To Sales Ratio		-0.49	1.0	-0.22	-0.43	-0.52	0.57	-0.49	1.0	-0.48	-0.54	1.0	0.15	1.0	-0.23	1.0	-0.3	-0.55	-0.8	-0.82	-0.57	0.49	0.91	0.46	-0.53	-0.48
Ptb Ratio	-0.49		-0.49	0.81	-0.37	-0.34	-0.99	1.0	-0.49	-0.41	0.83	-0.49	-0.87	-0.49	0.8	-0.49	0.91	1.0	0.5	0.44	0.99	-1.0	-0.61	-0.89	1.0	1.0
Days Sales Outstanding	1.0	-0.49		-0.22	-0.43	-0.53	0.57	-0.49	1.0	-0.48	-0.54	1.0	0.15	1.0	-0.24	1.0	-0.3	-0.56	-0.81	-0.82	-0.57	0.49	0.91	0.46	-0.54	-0.48
Book Value Per Share	-0.22	0.81	-0.22		-0.53	-0.59	-0.75	0.81	-0.22	-0.63	0.92	-0.22	-0.81	-0.22	0.8	-0.22	0.97	0.77	0.24	0.23	0.77	-0.8	-0.27	-0.85	0.78	0.78
Free Cash Flow Yield	-0.43	-0.37	-0.43	-0.53		0.91	0.3	-0.37	-0.43	0.93	-0.29	-0.43	0.75	-0.43	-0.7	-0.43	-0.46	-0.32	0.43	0.48	-0.31	0.39	-0.34	0.47	-0.34	-0.39
Operating Cash Flow Per Share	-0.52	-0.34	-0.53	-0.59	0.91		0.25	-0.34	-0.52	1.0	-0.26	-0.52	0.63	-0.52	-0.59	-0.52	-0.5	-0.28	0.53	0.39	-0.26	0.35	-0.5	0.33	-0.3	-0.35
Capex To Depreciation	0.57	-0.99	0.57	-0.75	0.3	0.25		-0.99	0.57	0.31	-0.81	0.57	0.83	0.57	-0.77	0.57	-0.86	-1.0	-0.58	-0.51	-1.0	0.99	0.69	0.88	-1.0	-0.99
Pb Ratio	-0.49	1.0	-0.49	0.81	-0.37	-0.34	-0.99		-0.49	-0.41	0.83	-0.49	-0.87	-0.49	0.8	-0.49	0.91	1.0	0.5	0.44	0.99	-1.0	-0.61	-0.89	1.0	1.0
Ev To Sales	1.0	-0.49	1.0	-0.22	-0.43	-0.52	0.57	-0.49		-0.48	-0.54	1.0	0.15	1.0	-0.23	1.0	-0.3	-0.55	-0.8	-0.82	-0.57	0.49	0.91	0.46	-0.53	-0.48
Free Cash Flow Per Share	-0.48	-0.41	-0.48	-0.63	0.93	1.0	0.31	-0.41	-0.48		-0.32	-0.48	0.7	-0.48	-0.64	-0.48	-0.55	-0.34	0.48	0.39	-0.33	0.42	-0.44	0.41	-0.36	-0.42
Roic	-0.54	0.83	-0.54	0.92	-0.29	-0.26	-0.81	0.83	-0.54	-0.32		-0.54	-0.74	-0.54	0.79	-0.54	0.92	0.82	0.55	0.47	0.83	-0.82	-0.59	-0.92	0.82	0.79
Inventory Turnover	1.0	-0.49	1.0	-0.22	-0.43	-0.52	0.57	-0.49	1.0	-0.48	-0.54		0.15	1.0	-0.24	1.0	-0.3	-0.55	-0.8	-0.82	-0.57	0.49	0.91	0.46	-0.53	-0.48
Net Income Per Share	0.15	-0.87	0.15	-0.81	0.75	0.63	0.83	-0.87	0.15	0.7	-0.74	0.15		0.15	-0.87	0.15	-0.85	-0.84	-0.14	0.01	-0.84	0.88	0.3	0.91	-0.85	-0.88
Days Of Inventory On Hand	1.0	-0.49	1.0	-0.22	-0.43	-0.52	0.57	-0.49	1.0	-0.48	-0.54	1.0	0.15		-0.23	1.0	-0.3	-0.55	-0.8	-0.82	-0.57	0.49	0.9	0.46	-0.53	-0.48
Payables Turnover	-0.23	0.8	-0.24	0.8	-0.7	-0.59	-0.77	0.8	-0.23	-0.64	0.79	-0.24	-0.87	-0.23		-0.23	0.81	0.79	0.3	0.24	0.79	-0.81	-0.33	-0.85	0.79	0.8
Capex To Revenue	1.0	-0.49	1.0	-0.22	-0.43	-0.52	0.57	-0.49	1.0	-0.48	-0.54	1.0	0.15	1.0	-0.23		-0.3	-0.55	-0.8	-0.82	-0.57	0.49	0.9	0.46	-0.53	-0.47
Cash Per Share	-0.3	0.91	-0.3	0.97	-0.46	-0.5	-0.86	0.91	-0.3	-0.55	0.92	-0.3	-0.85	-0.3	0.81	-0.3		0.88	0.39	0.32	0.88	-0.9	-0.42	-0.89	0.89	0.88
Pocfratio	-0.55	1.0	-0.56	0.77	-0.32	-0.28	-1.0	1.0	-0.55	-0.34	0.82	-0.55	-0.84	-0.55	0.79	-0.55	0.88		0.56	0.49	1.0	-1.0	-0.67	-0.89	1.0	0.99
Interest Coverage	-0.8	0.5	-0.81	0.24	0.43	0.53	-0.58	0.5	-0.8	0.48	0.55	-0.8	-0.14	-0.8	0.3	-0.8	0.39	0.56		0.82	0.57	-0.49	-0.92	-0.47	0.54	0.48
Capex To Operating Cash Flow	-0.82	0.44	-0.82	0.23	0.48	0.39	-0.51	0.44	-0.82	0.39	0.47	-0.82	0.01	-0.82	0.24	-0.82	0.32	0.49	0.82		0.5	-0.44	-0.73	-0.26	0.48	0.42
Pfcf Ratio	-0.57	0.99	-0.57	0.77	-0.31	-0.26	-1.0	0.99	-0.57	-0.33	0.83	-0.57	-0.84	-0.57	0.79	-0.57	0.88	1.0	0.57	0.5		-0.99	-0.69	-0.89	1.0	0.99
Days Payables Outstanding	0.49	-1.0	0.49	-0.8	0.39	0.35	0.99	-1.0	0.49	0.42	-0.82	0.49	0.88	0.49	-0.81	0.49	-0.9	-1.0	-0.49	-0.44	-0.99		0.61	0.89	-1.0	-1.0
Income Quality	0.91	-0.61	0.91	-0.27	-0.34	-0.5	0.69	-0.61	0.91	-0.44	-0.59	0.91	0.3	0.9	-0.33	0.9	-0.42	-0.67	-0.92	-0.73	-0.69	0.61		0.6	-0.65	-0.61
Roe	0.46	-0.89	0.46	-0.85	0.47	0.33	0.88	-0.89	0.46	0.41	-0.92	0.46	0.91	0.46	-0.85	0.46	-0.89	-0.89	-0.47	-0.26	-0.89	0.89	0.6		-0.89	-0.88
Ev To Operating Cash Flow	-0.53	1.0	-0.54	0.78	-0.34	-0.3	-1.0	1.0	-0.53	-0.36	0.82	-0.53	-0.85	-0.53	0.79	-0.53	0.89	1.0	0.54	0.48	1.0	-1.0	-0.65	-0.89		1.0
Pe Ratio	-0.48	1.0	-0.48	0.78	-0.39	-0.35	-0.99	1.0	-0.48	-0.42	0.79	-0.48	-0.88	-0.48	0.8	-0.47	0.88	0.99	0.48	0.42	0.99	-1.0	-0.61	-0.88	1.0

Click cells to compare fundamentals

Monte Rosa Account Relationship Matchups

Monte Rosa fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Ptb Ratio	(19.13)	2.73	1.32	1.62	2.3	2.42
Book Value Per Share	(1.11)	7.47	5.75	3.49	3.02	2.45
Free Cash Flow Yield	(0.0284)	(0.0727)	(0.29)	(0.22)	0.0741	0.0778
Operating Cash Flow Per Share	(0.52)	(1.28)	(1.96)	(0.85)	0.57	0.6
Capex To Depreciation	6.31	4.56	3.45	3.06	0.49	0.47
Pb Ratio	(19.13)	2.73	1.32	1.62	2.3	2.42
Free Cash Flow Per Share	(0.6)	(1.48)	(2.23)	(1.22)	0.51	0.54
Roic	(1.4)	(0.2)	(0.34)	(0.55)	(0.29)	(0.31)
Net Income Per Share	(0.82)	(1.55)	(2.22)	(2.63)	(0.98)	(1.03)
Cash Per Share	0.95	7.44	5.57	4.52	5.04	3.15
Pocfratio	(40.43)	(16.01)	(3.89)	(6.63)	12.21	12.82
Capex To Operating Cash Flow	(0.15)	(0.16)	(0.14)	(0.43)	0.095	0.0997
Pfcf Ratio	(35.25)	(13.75)	(3.41)	(4.62)	13.5	14.17
Days Payables Outstanding	4.8K	1.1K	335.28	654.21	752.34	714.72
Roe	0.74	(0.21)	(0.39)	(0.76)	(0.33)	(0.31)
Ev To Operating Cash Flow	(41.56)	(10.18)	(3.8)	(4.76)	7.89	8.29
Pe Ratio	(25.84)	(13.21)	(3.44)	(2.15)	(7.06)	(7.41)
Ev To Free Cash Flow	(36.23)	(8.74)	(3.34)	(3.32)	8.72	9.16
Earnings Yield	(0.0387)	(0.0757)	(0.29)	(0.47)	(0.14)	(0.15)
Net Debt To E B I T D A	(0.95)	4.89	0.0792	0.6	2.24	2.35
Current Ratio	1.49	20.96	10.79	5.07	2.4	2.28
Tangible Book Value Per Share	(1.11)	7.47	5.75	3.49	3.02	2.45
Shareholders Equity Per Share	(1.11)	7.47	5.75	3.49	3.02	2.45
Capex Per Share	0.077	0.21	0.27	0.37	0.054	0.0513
Graham Net Net	(1.28)	7.03	4.19	2.11	2.12	1.84
Enterprise Value Over E B I T D A	(34.87)	(8.54)	(3.52)	(1.52)	(4.09)	(4.29)
Price Earnings Ratio	(25.84)	(13.21)	(3.44)	(2.15)	(7.06)	(7.41)
Price Book Value Ratio	(19.13)	2.73	1.32	1.62	2.3	2.42
Days Of Payables Outstanding	4.8K	1.1K	335.28	654.21	752.34	714.72
Price To Operating Cash Flows Ratio	(40.43)	(16.01)	(3.89)	(6.63)	12.21	12.82
Price To Free Cash Flows Ratio	(35.25)	(13.75)	(3.41)	(4.62)	13.5	14.17

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

When determining whether Monte Rosa Therapeutics is a strong investment it is important to analyze Monte Rosa's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Monte Rosa's future performance. For an informed investment choice regarding Monte Stock, refer to the following important reports:

How To Invest In Monte

Details

Is Monte Stock a good investment?

Details

What is Monte Rosa's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the Bonds Directory module to find actively traded corporate debentures issued by US companies.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Monte Rosa. If investors know Monte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Monte Rosa listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.98)

Revenue Per Share

1.023

Return On Assets

(0.14)

Return On Equity

(0.36)

The market value of Monte Rosa Therapeutics is measured differently than its book value, which is the value of Monte that is recorded on the company's balance sheet. Investors also form their own opinion of Monte Rosa's value that differs from its market value or its book value, called intrinsic value, which is Monte Rosa's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Monte Rosa's market value can be influenced by many factors that don't directly affect Monte Rosa's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Monte Rosa's value and its price as these two are different measures arrived at by different means. Investors typically determine if Monte Rosa is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Monte Rosa's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Shareholders Equity Per Share	Debt To Equity
Capex Per Share	Graham Net Net
Average Receivables	Revenue Per Share
Interest Debt Per Share	Debt To Assets
Enterprise Value Over E B I T D A	Short Term Coverage Ratios
Price Earnings Ratio	Operating Cycle
Price Book Value Ratio	Price Earnings To Growth Ratio
Days Of Payables Outstanding	Dividend Payout Ratio
Price To Operating Cash Flows Ratio	Price To Free Cash Flows Ratio
Pretax Profit Margin	Ebt Per Ebit
Operating Profit Margin	Effective Tax Rate
Company Equity Multiplier	Long Term Debt To Capitalization
Total Debt To Capitalization	Return On Capital Employed
Debt Equity Ratio	Ebit Per Revenue
Quick Ratio	Dividend Paid And Capex Coverage Ratio
Net Income Per E B T	Cash Ratio
Cash Conversion Cycle	Operating Cash Flow Sales Ratio
Days Of Inventory Outstanding	Days Of Sales Outstanding
Free Cash Flow Operating Cash Flow Ratio	Cash Flow Coverage Ratios
Price To Book Ratio	Fixed Asset Turnover
Capital Expenditure Coverage Ratio	Price Cash Flow Ratio
Enterprise Value Multiple	Debt Ratio
Cash Flow To Debt Ratio	Price Sales Ratio
Return On Assets	Asset Turnover
Net Profit Margin	Gross Profit Margin
Price Fair Value	Return On Equity

Monte Historical Financial Ratios

About Monte Financial Ratios Analysis

Monte Rosa Financial Ratios Chart

Price To Sales Ratio

Ev To Sales

Inventory Turnover

Monte Rosa fundamentals Correlations

Monte Rosa Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Monte Rosa fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Days Sales Outstanding	+ 1.0	Price To Sales Ratio
Ev To Sales	+ 1.0	Price To Sales Ratio
Inventory Turnover	+ 1.0	Price To Sales Ratio
Days Of Inventory On Hand	+ 1.0	Price To Sales Ratio
Capex To Revenue	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio

Pe Ratio	- 1.0	Days Payables Outstanding
Ev To Operating Cash Flow	- 1.0	Days Payables Outstanding
Days Payables Outstanding	- 1.0	Pocfratio
Days Payables Outstanding	- 1.0	Pb Ratio
Ev To Operating Cash Flow	- 1.0	Capex To Depreciation
Pfcf Ratio	- 1.0	Capex To Depreciation